UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Journal of clinical oncology, 2013-06, Vol.31 (16), p.1970-1976

2013

Volltextzugriff (PDF)

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

Journal of clinical oncology, 2012-09, Vol.30 (27), p.3383-3388

2012

Volltextzugriff (PDF)

Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma

Journal of clinical oncology, 2008-11, Vol.26 (32), p.5165-5169

2008

Volltextzugriff (PDF)

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Journal of clinical oncology, 2010-06, Vol.28 (17), p.2853-2858

2010

Volltextzugriff (PDF)

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5027-5033

2005

Volltextzugriff (PDF)

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Blood advances, 2021-03, Vol.5 (5), p.1483-1489

2021

Volltextzugriff (PDF)

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.324-332

2017

Volltextzugriff (PDF)

BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2246-2252

2010

Volltextzugriff (PDF)

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

Leukemia & lymphoma, 2011-03, Vol.52 (3), p.394-399

2011

Volltextzugriff (PDF)

A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer

Clinical cancer research, 2001-12, Vol.7 (12), p.3920-3927

2001

Volltextzugriff (PDF)

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels

Molecular cancer therapeutics, 2008-04, Vol.7 (4), p.749-758

2008

Volltextzugriff (PDF)

Mantle cell lymphoma : A clinicopathologic study of 80 cases

Blood, 1997-03, Vol.89 (6), p.2067-2078

1997

Volltextzugriff (PDF)

Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1558-1558

1999

Volltextzugriff (PDF)

Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen

Journal of clinical oncology, 2002-12, Vol.20 (24), p.4649-4654

2002

Volltextzugriff (PDF)

The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases

Leukemia & lymphoma, 2004-03, Vol.45 (3), p.519-528

2004

Volltextzugriff (PDF)

Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma

Oncology (Williston Park, N.Y.), 2004-11, Vol.18 (13 Suppl 10), p.25

Klasa, Richard J

2004

Volltextzugriff (PDF)

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet (British edition), 2017-08, Vol.390 (10094), p.555-566

2017

Volltextzugriff (PDF)

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs

Molecular cancer therapeutics, 2007-03, Vol.6 (3), p.844-855

2007

Volltextzugriff (PDF)

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Blood, 2007-03, Vol.109 (5), p.1857-1861

2007

Volltextzugriff (PDF)

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

Blood, 2009-09, Vol.114 (11), p.2273-2279

2009

Volltextzugriff (PDF)

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

Blood, 2010-01, Vol.115 (2), p.289-295

2010

Volltextzugriff (PDF)

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Blood, 2006-11, Vol.108 (10), p.3295-3301

2006

Volltextzugriff (PDF)

Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era

British journal of haematology, 2017-01, Vol.176 (2), p.210-221

2017

Volltextzugriff (PDF)

Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide

Clinical cancer research, 2000-06, Vol.6 (6), p.2492-2500

2000

Volltextzugriff (PDF)

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)

Blood, 2005-09, Vol.106 (6), p.2169-2174

2005

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(106)

Publikationsform

Sprache

Englisch
(118)

Erscheinungsjahr

n.n

Thema

Humans
(58)
Science & Technology
(57)
Life Sciences & Biomedicine
(56)
Male
(41)
Female
(35)
Middle Aged
(35)
Oncology
(33)
Adult
(32)
Aged
(31)
Hematology
(30)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Aged, 80 And Over
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(21)
Hematologic And Hematopoietic Diseases
(17)
Prognosis
(16)
Treatment Outcome
(15)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(14)
Lymphoma
(14)
Rituximab
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era

Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British Columbia

Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines

Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study

A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)

A Phase I Dose-finding Study of Combined Treatment with an Antisense Bcl-2 Oligonucleotide (Genasense) and Mitoxantrone in Patients with Metastatic Hormone-refractory Prostate Cancer

Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels

Mantle cell lymphoma : A clinicopathologic study of 80 cases

Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation

Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen

The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases

Targeting the proapoptotic factor Bcl-2 in non-Hodgkin's lymphoma

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Diffuse large B‐cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era

Eradication of Human Non-Hodgkin’s Lymphoma in SCID Mice by BCL-2 Antisense Oligonucleotides Combined with Low-Dose Cyclophosphamide

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)

Suchergebnisse filtern